SCHEMBL3934889

SCHEMBL3934889

CC(C)(C)c1c(S(C)(=O)=O)ccc(N(C(=O)O)c2ncnc(Cl)c2CC=O)c1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930866 0.92
SCHEMBL3941386 0.88
SCHEMBL3930718 0.74
SCHEMBL3934886 0.74 GPR119 (0.37)
SCHEMBL3929669 0.62 GPR119 (0.36)
SCHEMBL4502806 0.60 MAP2K1 (0.33)
SCHEMBL782788 0.59 ALDH1A1 (0.36)
SCHEMBL3271020 0.59 FSCN1 (0.36)
SCHEMBL25208543 0.56
SCHEMBL15271545 0.54 ADORA2A (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222261-B2 Chemical compounds GlaxoSmithKline, LLC (US) 2012-07-17 US disclosed
US-20090318477-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2009-12-24 US disclosed
EP-2043744-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2009-04-08 EP disclosed
WO-2008008895-A1 GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO disclosed
WO-2008008887-A2 GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO disclosed